Study title: Open-label 40 weeks extension of study S-12159 to follow-up the long-term tolerability and efficacy of tenoxicam in children and adolescents suffering from juvenile rheumatoid arthritis (JRA) treated for up to one year.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Musculoskeletal Diseases [C05] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: TENOXICAM | |||||
ATC code: M01AC02 | |||||
Document link: | |||||
Document date: | |||||
Study number: S-12161 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |